Skip to main content
Equibles

APLMW · Apollomics Inc. · Investor Relations

Track APLMW — free

Use APLMW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APLMW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 0.00 (-7.34%)
Rebalance outlook locked
Market Cap
$65.08M
Shares
2.91M
Volume · Oct 23 100 Avg daily vol (3M) 16.82K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2024-08-16 August 2024 Corporate Presentation Presentation
2024-08-13 Canaccord Genuity 44th Annual Growth Conference Conference
2024-06-04 ASCO 2024: Efficacy and Safety of Vebreltinib in Patients With Advanced NSCLC Harboring Met-Exon 14-Skipping: Results of 2.5 Year Follow-Up in KUNPENG Event
2024-06-04 ASCO 2024: Efficacy and safety of the vebreltinib in previously treated, IDH mutant high-grade glioma patients with PTPRZ1-MET FUsion GENe (FUGEN): a randomized, multicentre, open-label, phase II/III trial Event
2024-04-10 AACR Annual Meeting 2024: Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels Shareholder meeting
2024-04-10 AACR Annual Meeting 2024: Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor Shareholder meeting
2024-03-28 Apollomics Full Year 2023 Earnings Conference Call Earnings call
2024-02-14 Oppenheimer 34th Annual Healthcare Life Sciences Conference Conference
2023-12-04 2023 IASLC North America Conference on Lung Cancer, December 2023 poster presentation (Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases) Conference
2023-10-26 ESMO 2023 oral presentation (Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: a real-life cohort analysis from Veneto Institute of Oncology, Padua, Italy) Presentation
2023-10-23 ESMO 2023 poster presentation (Preliminary Results of Phase II KUNPENG Study of Vebreltinib in Patients (Pts) with Advanced NSCLC Harboring c-MET Alterations) Presentation
2023-09-15 IASLC 2023 World Conference on Lung Cancer, September 2023 poster presentation Conference
2023-09-13 HC Wainwright 25th Annual Global Investment Conference Presentation Conference
2023-04-14 The 23rd Annual R. Bryan Miller Symposium Event

Source: https://ir.apollomicsinc.com/

Key facts CIK 1944885 CUSIP G0411D123 Visit website Investor relations